This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
High bloodpressure, also known as hypertension, is a common condition that affects millions of people worldwide. Understanding how high bloodpressure impacts your heart and learning to manage it can significantly reduce your risk of heart disease and improve your overall health. What Is High BloodPressure?
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce bloodpressure. mmHg in office systolic bloodpressure (oSBP) at six months when compared to control patients. Suman Pasupuleti, M.D.
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
PAD is a serious, progressive cardiovascular disease primarily caused by a buildup of fatty plaque in the blood vessels, or atherosclerosis. This plaque narrows the blood vessels and reduces blood flow to the legs and feet, which may significantly impair physical function, walking performance and quality of life.
1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. However, the development of atherosclerosis is now known to be much more complex, with a key role for immune cells and inflammation in conjunction with hyperlipidemia and elevated LDL levels.7 μ/L on 0.6
The focus will be on the intricate interplay between cardiorenal and metabolic conditions, such as type 2 diabetes, cardiovascular disease, and chronic kidneydisease, driven by lifestyle and health factors. Shapiro, DO Back By Popular Demand!
IntroductionAtherosclerosis, the hardening and narrowing of the arteries, occurs due to the buildup of plaque on the inner walls of the arteries which can result in reduced blood flow to the organs and tissues. Risk factors such as smoking, chronic kidneydisease, and aging can contribute to plaque formation.
Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. female, 22.1% female, 22.1%
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content